Business
European patent application allowed for grant
European patent application allowed for grant.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3793E Scancell Holdings Plc 09 February 2018 \n\n9 February 2018\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nContinued expansion of Intellectual Property Portfolio- Moditope® European patent application allowed for grant\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, notes that European Patent Office has announced its intention to grant Scancell's application for a European patent for its Moditope® immunotherapy platform.\n \nThis case is key to the protection of the Company's pipeline of Moditope® vaccines for the treatment of cancer and will provide commercial exclusivity in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey. Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US. \n \nCliff Holloway, Chief Executive Officer of Scancell, commented:\n \n\"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate. This is a key case for the Company as we progress development of our Moditope® platform and provides further protection for Scancell's innovative cancer vaccine technologies.\"\n \nFor Further Information: \n \n\n\n\n\nScancell\n\n\n\n\n\n\n\n\n\n\nDr John Chiplin, Chairman\nDr Cliff Holloway, CEO\n\n\nScancell Holdings Plc\n\n\n+1 858 361 6288\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFreddy Crossley (Corporate Finance)\nTom Salvesen (Corporate Broking)\n\n\nPanmure Gordon & Co\n\n\n+44 (0) 20 7886 2500\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMo Noonan/Simon Conway\n\n\nFTI Consulting\n\n\n+44 (0) 20 3727 1000\n\n\n\n\n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. \n \nScancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma...